XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segment Information (Notes)
 6 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Business Segment Information Business Segment Information
We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.
Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recast in the financial tables below for comparability.
Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs.
Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.
Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world.
We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.
For the three and six months ended September 30, 2020, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
Financial information for each of our segments is presented in the following table:
 Three Months Ended September 30, Six Months Ended September 30,
 2020201920202019
Revenues:
Healthcare $470,927 $485,283 $870,585 $931,015 
Applied Sterilization Technologies169,547 152,907 321,909 307,193 
Life Sciences115,658 98,650 232,570 195,435 
Total revenues$756,132 $736,840 $1,425,064 $1,433,643 
Operating income (loss):
Healthcare$104,796 $103,035 $187,153 $193,550 
Applied Sterilization Technologies76,835 65,386 140,790 133,421 
Life Sciences46,433 32,315 94,894 65,354 
Corporate(58,155)(50,956)(110,522)(106,353)
Total operating income before adjustments$169,909 $149,780 $312,315 $285,972 
Less: Adjustments
Amortization of acquired intangible assets (1)
$21,955 $18,952 $39,455 $35,901 
Acquisition and integration related charges (2)
1,135 1,947 2,421 3,864 
Redomiciliation and tax restructuring costs (3)
384 1,016 554 2,786 
Net (gain) loss on divestiture of businesses (1)
(5)50 5 2,476 
Amortization of property "step up" to fair value (1)
714 446 1,317 1,181 
COVID-19 incremental costs (4)
4,539 — 13,209 — 
Restructuring charges (5)
(76)636 90 2,943 
Total operating income$141,263 $126,733 $255,264 $236,821 
(1) For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
(3) Costs incurred in connection with the Redomiciliation.
(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.
(5) For more information regarding our restructuring efforts refer to Note 2 titled, "Restructuring".

Additional information regarding our fiscal 2021 and fiscal 2020 revenue is disclosed in the following tables:
 Three Months Ended September 30, Six Months Ended September 30,
 2020201920202019
Healthcare:
Capital equipment$131,673 $152,631 $259,755 273,486
Consumables122,797 116,033 206,551 232,115
Service216,457 216,619 404,279 425,414 
Total Healthcare Revenues $470,927 $485,283 $870,585 $931,015 
Applied Sterilization Technologies Service Revenues$169,547 $152,907 $321,909 $307,193 
Life Sciences:
Capital equipment
$29,241 $26,462 $59,671 $53,231 
Consumables55,793 42,540 114,635 86,569 
Service30,624 29,648 58,264 55,635 
Total Life Sciences Revenues$115,658 $98,650 $232,570 $195,435 
Total Revenues$756,132 $736,840 $1,425,064 $1,433,643 
Three Months Ended September 30, Six Months Ended September 30,
2020201920202019
Revenues:
Ireland$17,090 $15,171 $31,463 $30,279 
United States549,449 538,101 1,041,157 1,049,253 
Other locations189,593 183,568 352,444 354,111 
Total Revenues
$756,132 $736,840 $1,425,064 $1,433,643 
Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.
Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
September 30, 2020March 31, 2020
Assets:
Healthcare and Life Sciences$2,642,515 $2,705,377 
Applied Sterilization Technologies2,850,052 2,720,205 
Total assets
$5,492,567 $5,425,582